Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial

Clinical Lymphoma, Myeloma and Leukemia

Volumn 15, Issue 9, 2015, Pages 519-530

  Weisel, Katja ^a   Dimopoulos, Meletios ^b   Song, Kevin W ^c   Moreau, Philippe ^d   Palumbo, Antonio ^e   Belch, Andrew ^f   Schey, Stephen ^g   Sonneveld, Pieter ^h   Sternas, Lars ⁱ   Yu, Xin ⁱ   Amatya, Ramesh ^j   Gibson, Craig J ⁱ   Zaki, Mohamed ⁱ   Jacques, Christian ⁱ   San Miguel, Jesus ^k  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b ALEXANDRA HOSPITAL   (Greece)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

^d HÔTEL DIEU   (France)

^e CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^f UNIVERSITY OF ALBERTA   (Canada)

^g KING S COLLEGE HOSPITAL   (United Kingdom)

^h ERASMUS MEDICAL CENTER   (Netherlands)

ⁱ CELGENE CORPORATION   (United States)

^j ADELPHI REAL WORLD   (United Kingdom)

^k HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

more..

Author keywords

Low dose dexamethasone; Multiple myeloma; Pomalidomide; Quality of life; Relapsed Refractory

Indexed keywords

DEXAMETHASONE; POMALIDOMIDE; ANTINEOPLASTIC AGENT; BORTEZOMIB; LENALIDOMIDE; THALIDOMIDE;

ADULT; AGED; ARTICLE; CANCER FATIGUE; CANCER PAIN; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; INTENTION TO TREAT ANALYSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; TUMOR RECURRENCE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORTEZOMIB; DEXAMETHASONE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; QUALITY OF LIFE; THALIDOMIDE;

EID: 84939563744     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2015.05.007     Document Type: Article

References (52)

1. Durie BGM. Concise review of the disease and treatment options: multiple myeloma cancer of the bone marrow. International Myeloma Foundation 2011/2012.
2. K. Jordan, I. Proskorovsky, P. Lewis, and et al. Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study Support Care Cancer 22 2014 417 426
3. F. Mols, S. Oerlemans, A.H. Vos, and et al. Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population-based study using the PROFILES registry Eur J Haematol 89 2012 311 319
4. A.T. Johnsen, D. Tholstrup, M.A. Petersen, and et al. Health related quality of life in a nationally representative sample of haematological patients Eur J Haematol 83 2009 139 148
5. A. Molassiotis, B. Wilson, S. Blair, and et al. Unmet supportive care needs, psychological well-being and quality of life in patients living with multiple myeloma and their partners Psychooncology 20 2011 88 97
6. R.A. Kyle, M.A. Gertz, T.E. Witzig, and et al. Review of 1027 patients with newly diagnosed multiple myeloma Mayo Clin Proc 78 2003 21 33
7. R.A. Kyle, and S.V. Rajkumar Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma Leukemia 23 2009 3 9
8. C. Nanni, E. Zamagni, M. Farsad, and et al. Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results Eur J Nucl Med Mol Imaging 33 2006 525 531
9. G. Pratt, O. Goodyear, and P. Moss Immunodeficiency and immunotherapy in multiple myeloma Br J Haematol 138 2007 563 579
10. A. Palumbo, M.V. Mateos, S. Bringhen, and et al. Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients? Blood Rev 25 2011 181 191
11. P.G. Richardson, M. Delforge, M. Beksac, and et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma Leukemia 26 2012 595 608
12. A. Palumbo, M. Attal, and M. Roussel Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival Clin Cancer Res 17 2011 1253 1263
13. H. Brenner, A. Gondos, and D. Pulte Recent major improvement in long-term survival of younger patients with multiple myeloma Blood 111 2008 2521 2526
14. S.Y. Kristinsson, O. Landgren, P.W. Dickman, and et al. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003 J Clin Oncol 25 2007 1993 1999
15. Verelst S, Karim-Kos H, Blommestein H, et al. Are we making progress? Survival in plasma cell malignancies in the era of novel treatments a population based study of 17.790 patients in The Netherlands. Proceedings of the 17th Congress of the European Hematology Association (EHA), Amsterdam, The Netherlands. Haematologica 2012; 97:242 (abstract 0592).
16. Verelst SGR, Blommestein HM, Karim-Kos HE, et al. Trends in incidence and survival of multiple myeloma in the Netherlands in the last two decades. Results from a national population based study. Proceedings of the 53rd Annual Meeting of the American Society of Hematology (ASH), San Diego, CA. Blood 2011; 118:abstract 5071.
17. S.K. Kumar, A. Dispenzieri, M.Q. Lacy, and et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients Leukemia 28 2014 1122 1128
18. S.K. Kumar, J.H. Lee, J.J. Lahuerta, and et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study Leukemia 26 2012 149 157
19. A.K. Kvam, P. Fayers, M. Hjermstad, and et al. Health-related quality of life assessment in randomized controlled trials in multiple myeloma: a critical review of methodology and impact on treatment recommendations Eur J Haematol 83 2009 279 289
20. P. Sonneveld, S. Verelst, P. Lewis, and et al. Review of health-related quality of life data in multiple myeloma patients treated with novel agents Leukemia 27 2013 1959 1969
21. A.R. McCurdy, and M.Q. Lacy Pomalidomide and its clinical potential for relapsed or refractory multiple myeloma: an update for the hematologist Ther Adv Hematol 4 2013 211 216
22. L.G. Corral, P.A. Haslett, G.W. Muller, and et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha J Immunol 163 1999 380 386
23. J.S. Miguel, K. Weisel, P. Moreau, and et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomized, open-label, phase 3 trial Lancet Oncol 14 2013 1055 1066
24. H.J. Schunemann, and G.H. Guyatt Commentary - goodbye M(C)ID! Hello MID, where do you come from? Health Serv Res 40 2005 593 597
25. A.K. Kvam, F. Wisloff, and P.M. Fayers Minimal important differences and response shift in health-related quality of life; a longitudinal study in patients with multiple myeloma Health Qual Life Outcomes 8 2010 79
26. A.K. Kvam, P.M. Fayers, and F. Wisloff Responsiveness and minimal important score differences in quality-of-life questionnaires: a comparison of the EORTC QLQ-C30 cancer-specific questionnaire to the generic utility questionnaires EQ-5D and 15D in patients with multiple myeloma Eur J Haematol 87 2011 330 337
27. T.R. Osborne, C. Ramsenthaler, R.J. Siegert, and et al. What issues matter most to people with multiple myeloma and how well are we measuring them? A systematic review of quality of life tools Eur J Haematol 89 2012 437 457
28. N. Gulbrandsen, F. Wisloff, L. Brinch, and et al. Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support Med Oncol 18 2001 65 77
29. C.A. Uyl-de Groot, I. Buijt, I.J. Gloudemans, and et al. Health related quality of life in patients with multiple myeloma undergoing a double transplantation Eur J Haematol 74 2005 136 143
30. F. Wisloff, S. Eika, E. Hippe, and et al. Measurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group Br J Haematol 92 1996 604 613
31. F. Wisloff, and M. Hjorth Health-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma. Nordic Myeloma Study Group Br J Haematol 97 1997 29 37
32. K. Cocks, D. Cohen, F. Wisloff, and et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma Eur J Cancer 43 2007 1670 1678
33. M.L. Stead, J.M. Brown, G. Velikova, and et al. Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. European Organization for Research and Treatment of Cancer Study Group on Quality of Life Br J Haematol 104 1999 605 611
34. EORTC Quality of Life questionnaires. Available at: http://groups.eortc.be/qol/. Accessed: July 2013.
35. Cheung K, Oemar M, Oppe M, et al. On behalf of the EuroQol Group. EQ-5D User Guide. Basic information on how to use EQ-5D. version 2.0, March 2009. Available at: http://www.euroqol.org. Accessed: January 2014.
36. I. Proskorovsky, P. Lewis, C.D. Williams, and et al. Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma Health Qual Life Outcomes 12 2014 35
37. N.K. Aaronson, S. Ahmedzai, B. Bergman, and et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology J Natl Cancer Inst 85 1993 365 376
38. P. Dolan Modeling valuations for EuroQol health states Med Care 35 1997 1095 1108
39. Song KW, Dimopoulos MA, Weisel K, et al. Pomalidomide (POM) plus low-dose dexamethasone (LoDEX) improves health-related quality of life (HRQoL) vs high-dose dexamethasone (HiDEX) in relapsed refractory multiple myeloma (RRMM) patients enrolled in MM-003 phase 3 randomized trial. Proceedings of the 55th Annual Meeting of the American Society of Hematology (ASH), New Orleans, LA. Blood 2013; 122:abstract 2939.
40. S. Vadhan-Raj, R. von Moos, L.J. Fallowfield, and et al. Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid Ann Oncol 23 2012 3045 3051
41. N. Gulbrandsen, M.J. Hjermstad, and F. Wisloff Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences Eur J Haematol 72 2004 172 180
42. X. Leleu, M. Attal, B. Arnulf, and et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02 Blood 121 2013 1968 1975
43. P.G. Richardson, D. Siegel, R. Baz, and et al. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib Blood 121 2013 1961 1967
44. Pomalyst® (pomalidomide) [prescribing information]. Summit, NJ: Celgene Corporation; 2013.
45. Miguel J, Weisel K, Moreau P, et al. Efficacy, safety, and QOL in MM-003, a phase 3, multicenter, randomized, open-label study of pomalidomide (POM) + low-dose dexamethasone (LoDEX) vs high-dose dexamethasone (HiDEX) in RRMM. Proceedings of the 18th Congress of the European Hematology Association (EHA), Stockholm, Sweden. Haematologica 2013; 98:475:abstract S1151.
46. Song KW, Dimopoulos MA, Weisel KC, et al. Quality of life (QOL) improvements for pomalidomide plus low-dose dexamethasone (POM + LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients (pts) enrolled in MM-003. J Clin Oncol 2013; 31:abstract 8583.
47. E. Terpos, J. Berenson, R.J. Cook, and et al. Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease Leukemia 24 2010 1043 1049
48. F. Wisloff, A.K. Kvam, M. Hjorth, and et al. Serum calcium is an independent predictor of quality of life in multiple myeloma Eur J Haematol 78 2007 29 34
49. K. Strasser-Weippl, and H. Ludwig Psychosocial QOL is an independent predictor of overall survival in newly diagnosed patients with multiple myeloma Eur J Haematol 81 2008 374 379
50. M.Q. Lacy, J.B. Allred, M.A. Gertz, and et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease Blood 118 2011 2970 2975
51. M.Q. Lacy, S.R. Hayman, M.A. Gertz, and et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma J Clin Oncol 27 2009 5008 5014
52. M.Q. Lacy, S.R. Hayman, M.A. Gertz, and et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM) Leukemia 24 2010 1934 1939